Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40NG9 | ISIN: US83548R4020 | Ticker-Symbol: H3D0
NASDAQ
20.11.24
21:31 Uhr
2,910 US-Dollar
0,000
0,00 %
1-Jahres-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur SONNET BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SONNET BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
12.11.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Releases Virtual Investor '"What this Means" Segment2
08.11.Sonnet BioTherapeutics secures US patent covering two drug candidates4
06.11.Sonnet BioTherapeutics sets $5 million stock offering2
06.11.Sonnet BioTherapeutics kündigt Aktienemission im Wert von 5 Millionen US-Dollar an4
06.11.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules3
06.11.Sonnet BioTherapeutics secures patent for cancer drug candidates2
06.11.Sonnet BioTherapeutics erhält Patent für Krebsmedikamenten-Kandidaten10
06.11.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates193Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18...
► Artikel lesen
06.11.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report-
04.11.Sonnet BioTherapeutics Holdings, Inc. - S-1/A, General form for registration of securities3
28.10.Sonnet BioTherapeutics Holdings, Inc. - S-1, General form for registration of securities4
17.10.Sonnet BioTherapeutics erfüllt Nasdaq-Listungsanforderungen5
17.10.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
17.10.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq88PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs...
► Artikel lesen
10.10.Alkem Labs signs licensing agreement with Sonnet BioTherapeutics3
09.10.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report3
09.10.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India119 Sonnet to receive $1.0 million in upfront payment and up to an additional$1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the India...
► Artikel lesen
04.10.Sonnet BioTherapeutics secures tax credit approval2
04.10.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs103PRINCETON, NJ, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs...
► Artikel lesen
30.09.Sonnet BioTherapeutics enacts reverse stock split2
Seite:  Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1